In tracking life science investors worldwide, LSN’s research team has noticed that there are a growing number of Asia-based investors seeking global opportunities as well as investments in the U.S. and Asia.
GlaxoSmithKline (GSK.L) set out a roadmap for a potential 2016 flotation of its HIV medicines business on Wednesday as it hired three leading banks to advise on what would be the drug industry’s largest ever initial public share sale.
Chief Executive Andrew Witty said his company would take the next two to three months to analyze the pros and cons of an initial public offering (IPO), as well as deciding how much of ViiV to sell and where to list the shares.
Yanev Suissa, formerly a venture capitalist with New Enterprise Associates and a senior investment officer in the Bush and Obama administrations, is launching a new venture firm with a focus on companies doing business with the public sector.
The company’s debut fund has raised around $100 million and will focus primarily on Series A and B investments with the occasional Series C, which will likely include local companies. The firm, to be named SineWave Ventures, will officially launch in the region in the second half of the year.
UMD start-up SD Nanosciences has developed technology for creating targeted drug and vaccine delivery vehicles
When University of Maryland Professors Philip DeShong and Daniel Stein began tagging soap bubbles with biomolecules, they had no idea this technology would one day be poised to change the way drugs and vaccines fight against bacteria, viruses and cancer.
Notice is hereby given that the Office of Intramural Research (OIR), National Institutes of Health (NIH), will host two webinars to enable public discussion of its proposal to reorganize the OIR Office of Technology Transfer (OTT). The proposal seeks to align authority and responsibility for the implementation and execution of patenting and licensing (P&L) functions within the NIH Institutes and Centers.
MedImmune, the global biologics research and development arm of AstraZeneca, and The University of Manchester have entered into a new research collaboration to generate cutting-edge protein formulation science.
As part of the collaboration, MedImmune will work with researchers at Manchester’s Centre of Excellence in Biopharmaceuticals (COEBP) on testing and understanding the fundamental principles of protein solution behavior in order to find better ways to administer breakthrough medicines to patients.
Rockville-based Emergent BioSolutions will expand its Baltimore manufacturing facility and add 158 new jobs over the next four years. Emergent will potentially double its 58,000-square-foot space on Lombard Street to include additional manufacturing, labs and warehouse space.
After growing up on Cleveland’s east side, Bill Fuller headed for North Carolina in 1990. He returned briefly in the 2000s, but he didn’t think he’d ever come back. But when BioEnterprise asked him in 2013 to become its newest CEO-in-Residence, he couldn’t resist the opportunity.
In Palo Alto in the heart of Silicon Valley, hedge fund manager Joon Yun is doing a back-of-the-envelope calculation. According to US social security data, he says, the probability of a 25-year-old dying before their 26th birthday is 0.1%. If we could keep that risk constant throughout life instead of it rising due to age-related disease, the average person would – statistically speaking – live 1,000 years. Yun finds the prospect tantalising and even believable. Late last year he launched a $1m prize challenging scientists to “hack the code of life” and push human lifespan past its apparent maximum of about 120 years (the longest known/confirmed lifespan was 122 years).
Maryland is giving biotech firm Emergent BioSolutions a $2 million loan to double its footprint and staff in East Baltimore.
Emergent BioSolutions, which develops vaccines and other pharmaceuticals, will double its 58,000-square-foot manufacturing facility on Lombard Street to include more space for manufacturing, quality control cabs and warehouse space. Emergent expects to break ground on the expansion in the second quarter of 2015.